Iisrael - inglise - Ministry of Health

roche pharmaceuticals (israel) ltd - tocilizumab - solution for injection - tocilizumab 162 mg / 0.9 ml - tocilizumab - - actemra in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease modifying anti rheumatic drugs (dmards) or tumor necrosis factor (tnf) antagonists. in these patients, actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. - actemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. - actemra in combination with methotrexate (mtx) in indicated for the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx - actemra (tocilizumab) is indicated for the treatment of giant cell arteritis (gca) in adult patients. - actemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. actemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. - actemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. actemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.

Saudi Araabia - inglise - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

roche, switzerland - tocilizumab - concentrate for solution for infusion - 20 mg/ml

Saudi Araabia - inglise - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

roche, switzerland - tocilizumab - concentrate for solution for infusion - 20 mg/ml

Saudi Araabia - inglise - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

roche, switzerland - tocilizumab - concentrate for solution for infusion - 20 mg/ml

Saudi Araabia - inglise - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

roche, switzerland - tocilizumab - solution for injection - 180 mg/ml

Jordaania - inglise - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - tocilizumab 200 mg/10ml - 200 mg/10ml

Jordaania - inglise - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - tocilizumab 400 mg/20ml - 400 mg/20ml

Jordaania - inglise - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - tocilizumab 80 mg/4ml - 80 mg/4ml

Jordaania - inglise - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - tocilizumab 162 mg/0.9 ml - 162 mg/0.9 ml

Armeenia - inglise - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

f. hoffmann-la roche ltd. - tocilizumab - concentrate for solution for i/v infusion - 20mg/ml